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Emergence of a Potent Multidrug Efflux Pump Variant That Enhances
Campylobacter Resistance to Multiple Antibiotics
Abstract
Bacterial antibiotic efflux pumps are key players in antibiotic resistance. Although their role in conferring
multidrug resistance is well documented, the emergence of “super” efflux pump variants that enhance bacterial
resistance to multiple drugs has not been reported. Here, we describe the emergence of a resistance-enhancing
variant (named RE-CmeABC) of the predominant efflux pump CmeABC in Campylobacter, a major zoonotic
pathogen whose resistance to antibiotics is considered a serious antibiotic resistance threat in the United
States. Compared to the previously characterized CmeABC transporters, RE-CmeABC is much more potent
in conferring Campylobacter resistance to antibiotics, which was shown by increased MICs and reduced
intracellular accumulation of antibiotics. Structural modeling suggests that sequence variations in the drug-
binding pocket of CmeB possibly contribute to the enhanced efflux function. Additionally, RE-CmeABC
expands the mutant selection window of ciprofloxacin, enhances the emergence of antibiotic-resistant
mutants, and confers exceedingly high-level resistance to fluoroquinolones, an important class of antibiotics
for clinical therapy of campylobacteriosis. Furthermore, RE-CmeABC is horizontally transferable, shifts
antibiotic MIC distribution among clinical isolates, and is increasingly prevalent in Campylobacter jejuni
isolates, suggesting that it confers a fitness advantage under antimicrobial selection. These findings reveal a
new mechanism for enhanced multidrug resistance and an effective strategy utilized by bacteria for adaptation
to selection from multiple antibiotics.
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ABSTRACT Bacterial antibiotic efflux pumps are key players in antibiotic resistance. Although their role in conferring multi-
drug resistance is well documented, the emergence of “super” efflux pump variants that enhance bacterial resistance to multiple
drugs has not been reported. Here, we describe the emergence of a resistance-enhancing variant (named RE-CmeABC) of the
predominant efflux pump CmeABC in Campylobacter, a major zoonotic pathogen whose resistance to antibiotics is considered a
serious antibiotic resistance threat in the United States. Compared to the previously characterized CmeABC transporters, RE-
CmeABC is muchmore potent in conferring Campylobacter resistance to antibiotics, which was shown by increasedMICs and
reduced intracellular accumulation of antibiotics. Structural modeling suggests that sequence variations in the drug-binding
pocket of CmeB possibly contribute to the enhanced efflux function. Additionally, RE-CmeABC expands the mutant selection
window of ciprofloxacin, enhances the emergence of antibiotic-resistant mutants, and confers exceedingly high-level resistance
to fluoroquinolones, an important class of antibiotics for clinical therapy of campylobacteriosis. Furthermore, RE-CmeABC is
horizontally transferable, shifts antibiotic MIC distribution among clinical isolates, and is increasingly prevalent in Campylo-
bacter jejuni isolates, suggesting that it confers a fitness advantage under antimicrobial selection. These findings reveal a new
mechanism for enhancedmultidrug resistance and an effective strategy utilized by bacteria for adaptation to selection frommul-
tiple antibiotics.
IMPORTANCE Bacterial antibiotic efflux pumps are ubiquitously present in bacterial organisms and protect bacteria from the
antibacterial effects of antimicrobials and other toxic compounds by extruding them out of cells. Thus, these efflux transporters
represent an important mechanism for antibiotic resistance. In this study, we discovered the emergence and increasing preva-
lence of a unique efflux pump variant that is muchmore powerful in the efflux of antibiotics and confers multidrug resistance in
Campylobacter, which is a major foodborne pathogen transmitted to humans via the food chain. Unlike other specific resistance
determinants that only allow bacteria to resist a particular antimicrobial, the acquisition of a functionally enhanced efflux pump
will empower bacteria with simultaneous resistance to multiple classes of antibiotics. These findings reveal a previously unde-
scribed mechanism for enhancedmultidrug resistance and open a new direction for us to understand how bacteria adapt to anti-
biotic treatment.
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As evidenced by the recent emergence and spread of bacteriaresistant to the last-resort antibiotics (e.g., carbapenems and
colistin), the increasing prevalence of antibiotic-resistant patho-
gens has become a public health crisis (1–4). Different from other
antibiotic resistance mechanisms, bacterial multidrug efflux
pumps confer resistance to structurally diverse antimicrobials.
Among various types of efflux transporters, members of the
resistance-nodulation-cell division (RND) family are the most
important in mediating antibiotic resistance in Gram-negative
bacteria (5, 6). Typically, an RND efflux transporter is an inner
membrane protein. It interacts with a periplasmic fusion protein
and an outer membrane channel protein to assemble as a tripartite
efflux complex that spans the entire cell envelope and extrudes
antimicrobials directly out of bacterial cells (6). These RND
efflux transporters are commonly controlled by regulatory fac-
tors, and overexpression of these efflux transporters is typically
required for mediating clinically relevant levels of antibiotic
resistance (5–10). Recently, Blair et al. reported that a single
amino acid substitution in the drug-binding pocket of the AcrB
transporter enhanced the function of the efflux pump and con-
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ferred clinically relevant resistance in Salmonella (11), suggesting
an overexpression-independent mechanism for enhancing the
function of a multidrug-resistant transporter.
Thermophilic Campylobacter species, including Campylobac-
ter jejuni and Campylobacter coli, are major foodborne pathogens
and are among the most frequent causes of bacterial gastroenteri-
tis in humans, accounting for 400 million to 500 million cases of
diarrhea each year worldwide (12). Transmission of Campylobac-
ter bacteria to humans occurs mainly via the foodborne route, and
contaminated poultry meat, water, and milk are the main sources
of infection (13, 14). Because of the use of antibiotics in animal
agriculture and medical settings, antibiotic-resistant Campylobac-
ter is increasingly prevalent worldwide (15, 16). Because of its
rising prevalence and impact on public health, antibiotic-resistant
Campylobacter has been listed by the Centers for Disease Control
and Prevention as a serious antibiotic resistance threat in the
United States (17). In Campylobacter bacteria, the tripartite mul-
tidrug efflux pump CmeABC is the predominant efflux system
and plays a key role in mediating resistance to structurally diverse
antimicrobials (18). CmeABC constitutes the CmeB inner mem-
brane transporter, belonging to the RND protein family; the
CmeA periplasmic protein, a member of the membrane fusion
protein family; and the CmeC outer membrane channel protein.
This powerful efflux system is regulated primarily by CmeR and
secondarily by CosR, both of which bind to the promoter region of
the cmeABC operon and function as transcriptional repressors for
this efflux system (19, 20). Notably, CmeABC is important for
both intrinsic and acquired resistance to antibiotics, but overex-
pression of cmeABC confers only a modest increase in the MICs of
antibiotics compared with the base-level expression of the efflux
pump (19, 21).
In this study, we report the identification of a potent variant of
CmeABC that shows an enhanced efflux function. We show that
this variant CmeABC is highly potent against multiple antibiotics,
promotes the emergence of antibiotic-resistant mutants, and con-
fers exceedingly high-level resistance to fluoroquinolones. Addi-
tionally, we discovered that the cmeABC variant is increasingly
prevalent in C. jejuni isolates, indicating that it confers on Cam-
pylobacter a fitness advantage under antibiotic selection pressure.
To the best of our knowledge, this is the first report on the emer-
gence of a “super” efflux pump variant that empowers bacteria
with simultaneous resistance to multiple classes of drugs.
RESULTS
Identification of a unique CmeABC variant associated with re-
sistance to florfenicol and other antimicrobials. Florfenicol, the
fluorinated derivative of chloramphenicol, has been used for
treatment of respiratory diseases in food-producing animals, and
previously we reported a high prevalence of florfenicol resistance
in Campylobacter isolates in China (22). A C. coli isolate, DH161
(Table 1), was florfenicol resistant but did not harbor any known
mechanisms (e.g., mutations in rRNA or acquisition of floR, fexA,
fexB, cfr, or optrA) that confer florfenicol resistance, as determined
by PCR (see Table S3 in the supplemental material). A natural-
transformation assay revealed that florfenicol resistance in DH161
was transferrable between C. coli and C. jejuni. Specifically, the
MIC of florfenicol for transformant NT161 was 32-fold higher
than that for the recipient C. jejuni NCTC 11168 (Table 1). Nota-
bly, NT161 also showed increased resistance to other antibiotics,
including chloramphenicol (16-fold), ciprofloxacin (8-fold),
erythromycin (4-fold), and tetracycline (4-fold). These findings
indicated that the transformation resulted in the transfer of mul-
tidrug resistance, suggesting that either multiple antibiotic resis-
tance genes/mutations or a multidrug resistance mechanism was
transferred from DH161 to NT161. Subsequently, random trans-
poson mutagenesis of NT161 was conducted with EZ-Tn5 to
identify the specific mechanism responsible for florfenicol resis-
tance in the transformant, which led to the identification of the
transposon mutant NT161::aphA-3, which was susceptible to flo-
rfenicol. Determination of the transposon insertion site in
NT161::aphA-3 revealed the insertion of the EZ-Tn5 transposon
into a gene whose nucleotide sequence was 78.7% identical to that
of the native cmeB gene in NCTC 11168. Notably, compared with
NT161, NT161-aphA-3 showed a marked decrease in the MICs of
florfenicol (64-fold), chloramphenicol (64-fold), ciprofloxacin
(32-fold), erythromycin (32-fold), and tetracycline (64-
fold) (Table 1). These results suggest that a cmeABC-related mech-
anism was likely to be responsible for the elevated resistance to
florfenicol and other antimicrobials.
To further examine this possibility, we performed whole-
genome sequence analysis of NT161. Comparative analysis of the
draft genome of NT161 with the complete genome of NCTC
11168 (GenBank accession number NC_002163) revealed that a
5,691-bp segment containing the entire cmeABC operon of
DH161 replaced the same locus of NCTC 11168. Beyond this re-
placement, no other insertions/deletions or plausible single-
TABLE 1 Antimicrobial susceptibilities of the key Campylobacter strains used in this study
Strain Description
MIC (mg/liter)a of:
FFC CHL CIP ERY TET
DH161 C. coli from duck, isolated in 2009 16 256 256 4 512
NCTC 11168 C. jejuni reference strain 0.5 1 0.125 1 1
NT161 Transformant of NCTC 11168 carrying RE-cmeABC from DH161 16 16 1 4 4
NT161-aphA-3 NT161cmeABC::aphA-3 0.25 0.25 0.03 0.125 0.06
11168-V1 NCTC 11168 with RE-cmeABC of NT161 and its promoter sequence 16 16 1 4 4
11168-V2 NCTC 11168 with RE-cmeABC of NT161 but original promoter of cmeABC in NCTC 11168 4 4 0.5 2 2
81–176 C. jejuni reference strain 0.5 2 0.125 0.25 -
81–176-V 81-176 with RE-cmeABC of DH161 32 64 1 512 -
11168-C257T NCTC 11168 with C257T mutation in gyrA 0.5 1 16 1 1
NT161-C257T NT161 with C257T mutation in gyrA 16 16 256 4 4
a CHL, chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin; FFC, florfenicol; TET, tetracycline.
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nucleotide polymorphisms were observed in NT161. These results
indicated that the natural transformation led to allelic exchange of
cmeABC between the donor and recipient strains and acquisition
of cmeABC from DH161 elevated multidrug resistance in NT161.
Here we designate this CmeABC variant of DH161 RE-CmeABC
(resistance-enhancing CmeABC).
Functional confirmation of RE-CmeABC. To verify the func-
tion of RE-CmeABC, we replaced the cmeABC operon in NCTC
11168 with RE-cmeABC by gene-specific replacement by natural
transformation. PCR and Sanger sequencing confirmed the suc-
cessful allelic replacement in the transformant. As shown in Ta-
ble 1, transformant 11168-V1 showed 32-, 16-, 8-, 4-, and 4-fold
increases in the MICs of florfenicol, chloramphenicol, ciprofloxa-
cin, erythromycin, and tetracycline, respectively, compared to the
recipient strain NCTC 11168 (Table 1). In addition, we intro-
duced RE-cmeABC into a different C. jejuni strain, 81-176. We
first deleted the whole cmeABC operon natively present in 81-176
and then introduced RE-cmeABC into a different locus via natural
transformation. The 81-176 transformant with RE-cmeABC
(named 81-176-V) showed a marked increase in the MICs of flo-
rfenicol (64-fold), chloramphenicol (32-fold), and ciprofloxa-
cin (8-fold) compared with 81-176 with its native cmeABC operon
(Table 1). These results clearly show that RE-cmeABC confers sig-
nificantly higher MICs of different antibiotics.
Sequence analysis of the promoter region of RE-cmeABC indi-
cated the presence of an A¡ G mutation compared to the cme-
ABC promoter in NCTC 11168, resulting in an imperfect inverted
repeat in the CmeR-binding site. Previous studies have indicated
that the mutations in the CmeR-binding site result in overexpres-
sion of CmeABC in Campylobacter (20, 23). We compared the
cmeABC expression levels in 11168-V1 and NCTC 11168 by real-
time PCR. The results show a 5-fold increase in the expression of
cmeABC in 11168-V1 over that in NCTC 11168. To differentiate
the functional differences attributable to overexpression and se-
quence variation itself, we further constructed transformant
11168-V2 in which the original cmeABC coding region of NCTC
11168 was replaced with RE-cmeABC but it retained the native
promoter sequence of NCTC 11168. Real-time quantitative re-
verse transcription (RT)-PCR showed that RE-cmeABC in
11168-V2 was expressed at a level similar (P  0.05) to that of
cmeABC in NCTC 11168. However, the MICs of florfenicol, chlor-
amphenicol, ciprofloxacin, erythromycin, and tetracycline were
8-, 4-, 4-, 2-, and 2-fold higher, respectively, in 11168-V2 than in
NCTC 11168 (Table 1). These MIC differences were attributable
to sequence variations between the two cmeABC copies. Compar-
ison of 11168-V1 with 11168-V2 revealed 4-fold (for phenicols)
and 2-fold differences (for ciprofloxacin, erythromycin, and tet-
racycline), which were attributable to the increased expression of
RE-cmeABC. Thus, both sequence variation and enhanced expres-
sion contributed to the resistance-enhancing function of RE-
CmeABC.
We further performed accumulation assays to assess whether
RE-CmeABC extrudes more ciprofloxacin. Compared to NCTC
11168, 11168-V1 and 11168-V2 accumulated significantly less
ciprofloxacin (Fig. 1), while there was no significant difference in
ciprofloxacin accumulation between 11168-V1 and 11168-V2.
This result indicated that RE-CmeABC indeed has an enhanced
efflux function.
Contribution of RE-CmeABC to extremely high-level cipro-
floxacin resistance inCampylobacter isolates. Fluoroquinolone-
resistant Campylobacter is increasingly prevalent, and its resis-
tance is mediated by GyrA mutations in conjunction with the
function of CmeABC (15). Typically, fluoroquinolone-resistant
Campylobacter isolates have ciprofloxacin MICs ranging from 4 to
32 mg/liter (24). However, we noticed that DH161 had an ex-
tremely high ciprofloxacin MIC (256 mg/liter; Table 1). In addi-
tion, multiple C. jejuni isolates in our previous surveillance work
showed ciprofloxacin MICs of256 mg/liter (see Table S1 in the
supplemental material). These isolates harbored the known
C257T (Thr-86-Ile) mutation in gyrA, but there were no plasmid-
mediated quinolone resistance (PMQR) genes, as determined by
PCR (see Table S3). Thus, the C257T mutation alone could not
explain the extremely high ciprofloxacin MIC. We then sequenced
and analyzed the CmeABC operon in these C. jejuni isolates.
CmeA and CmeC in these isolates were homologous (98%
amino acid identities) to CmeA and CmeC in NCTC 11168, while
CmeB in these C. jejuni strains showed only ~81% amino acid
sequence identity to CmeB in NCTC 11168 but was highly homol-
ogous (99.5% amino acid sequence identity) to CmeB in C. coli
DH161, indicating that these C. jejuni isolates harbored RE-
CmeABC. Given that RE-CmeABC showed an enhanced function
in conferring antibiotic resistance, we hypothesized that the ex-
tremely high ciprofloxacin MIC was due to the synergistic action
of the CmeABC variant and the gyrA mutation. To prove this
possibility, the C257T mutation in gyrA was introduced into both
NCTC 11168 and NT161, which differed only in the cmeABC
operon. As shown in Table 1, the ciprofloxacin MIC for NT161
containing the C257T mutation was 256 mg/liter, while the cipro-
floxacin MIC for NCTC 11168 containing the C257T mutation
was 16 mg/liter, a 16-fold difference. These results strongly indi-
cate that RE-CmeABC together with the C257T mutation con-
ferred extremely high-level ciprofloxacin resistance.
RE-CmeABC increases the frequencies of emergence of
fluoroquinolone-resistant Campylobacter mutants. Previous
studies demonstrated that CmeABC contributes to the emergence
of fluoroquinolone-resistant Campylobacter mutants (21, 25).
Since RE-CmeABC, identified in this study, shows an enhanced
efflux function compared with the typical CmeABC efflux
pump, we speculated that RE-CmeABC could even further pro-
mote the emergence of fluoroquinolone-resistant Campylobac-
ter mutants under selection pressure. As shown in Table S2 in the
supplemental material, when ciprofloxacin was used at 1.25 or
FIG 1 Accumulation of ciprofloxacin in NCTC 11168, 11168-V1, and 11168-
V2. Each bar represents the mean and standard deviation of triplicate samples.
A t test was used to perform the statistical analysis. *, P 0.05; **, P 0.01.
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4 mg/liter to select the mutants, the frequency of emergence of
fluoroquinolone-resistant mutants was about 9-fold (P  0.05)
and 25-fold higher (P  0.05), respectively, in NT161 than in
NCTC 11168. Importantly, when a ciprofloxacin concentration of
8 or 16 mg/liter was used on the selective agar plates, no mutant
colonies of NCTC 11168 were detected, while the frequency of
mutant emergence in NT161 remained at ~108. These results
clearly indicate that the cmeABC variant expanded the mutant
selection window for fluoroquinolones and increased the fre-
quency of emergence of fluoroquinolone-resistant mutants under
antibiotic selection.
Structural modeling of CmeB suggests enhanced drug bind-
ing by the transporter. Generally, the CmeB amino acid se-
quences of C. jejuni and C. coli isolates are at least 93% identical
(Fig. 2a), but CmeB in RE-CmeABC is divergent, showing ~81%
homology with that of NCTC 11168. Interestingly, there are 18
CmeB homologs (from 18 different C. jejuni isolates) that are
similar to CmeB in RE-CmeABC in the GenBank database, most
of which were deposited in 2015. On the basis of phylogenetic
analysis, CmeB in RE-CmeABC and its 18 homologs formed a
unique subtree (shaded gray in Fig. 2a), which is apart from the
majority of the CmeB sequences of C. jejuni and C. coli in the
database.
To help understand how RE-CmeABC has an enhanced efflux
function, we compared the predicted structures of CmeB in RE-
CmeABC and CmeB in NCTC 11168 by homology modeling,
based on the crystal structure of the MexB membrane protein
(Protein Data Bank ID 2V50) (26) and with the Modeller program
(27). Protein sequence alignment suggests that MexB is 40%
identical to these two CmeB proteins. As expected, each predicted
CmeB structure constitutes 12 transmembrane helices (TMs 1 to
12) and two large extracellular loops protruding out of the inner
membrane and into the periplasmic space (Fig. 2b). These two
periplasmic loops are located between TMs 1 and 2 and between
FIG 2 Sequence analysis and structure prediction of CmeB. (a) Phylogenetic analysis of Campylobacter CmeB sequences identified in this study and deposited
in the GenBank database. Different Campylobacter species are shown in different colors as follows: red, C. coli; blue, C. jejuni; green, other Campylobacter species.
The purple square indicates CmeB of isolate DH161. The unique subtree of RE-CmeB and its homologs from C. jejuni and C. coli is shaded gray. The purple dot
indicates multidrug efflux RND transporter AcrB (accession number WP_044694729.1) from E. coli, which was used as the outgroup. (b) The CmeB structures
predicted by the Modeller program. For clarity, only the predicted periplasmic domain structures of NCTC 11168 CmeB (pink) and RE-CmeB (DH161, light
green) are shown. The 22 mutated residues located in the periplasmic drug-binding cavity of the mutant transporter are represented by green sticks. The
corresponding residues in wild-type CmeB are represented by cyan sticks. (c) The predicted bound ciprofloxacin molecules are magenta. The residues involved
in binding are represented by sticks. (d) The predicted bound florfenicol molecules are orange. The residues involved in binding are represented by sticks.
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TMs 7 and 8, respectively, generating a periplasmic domain of the
pump. As in AcrB (28, 29) and MexB (26), this periplasmic do-
main can be divided into six subdomains (PN1, PN2, PC1, PC2,
DN, and DC) (Fig. 2b). A cleft is formed between subdomains PC1
and PC2. This cleft is likely to create an entrance for different
substrates, allowing them to enter the pump through the
periplasm and outer leaflet of the inner membrane. Deep inside
the cleft, the pump forms a large internal cavity. In AcrB, this
cavity has been shown to form an important binding site that plays
a predominant role in recognizing substrates for export. Interest-
ingly, of the 198 amino acid differences between the NCTC 11168
and variant CmeB transporters, 22 are localized in this drug-
binding cavity (Fig. 2b).
To understand if these mutated residues in the variant trans-
porter are important for recognizing drug molecules, we used Au-
toDock Vina (30) to determine how CmeB binds drugs. Specifi-
cally, Vina was employed to predict the binding modes for
ciprofloxacin and florfenicol. The data suggest that these two
drugs are bound within the cavity between subdomains PC1 and
PC2 in both CmeB and the variant transporter. However, these
two transporters utilize different sets of residues to contact these
drugs. In CmeB of NCTC 11168, residues D80, T82, T92, Y94,
K811, L669, E676, Y678, T713, Q820, and Q822 are predicted to be
involved in the binding of ciprofloxacin (Fig. 2c), while the variant
transporter may use I136, V139, S141, I178, P289, I291, L282,
V605, L607, F625, I627, Y328, V568, and L662 to bind ciprofloxa-
cin (Fig. 2c). For florfenicol binding, CmeB of NCTC 11168 is
likely to employ residues I573, N575, D612, L613, S616, S657,
I659, T713, D715, R711, T716, and Q822 to interact with the drug
(Fig. 2d); however, the variant transporter may utilize residues
I178, I136, V139, P289, I291, Y328, V568, V605, L607, F625, and
L662 to bind florfenicol (Fig. 2d). Interestingly, on the basis of the
prediction, it was found that the variant transporter tends to use
the mutated residues, including I136, V139, I291, V605, and L607,
to bind these drugs. The ciprofloxacin- and florfenicol-binding
energies of CmeB of NCTC 11168 are predicted to be 7.4 and
6.6 kcal/mol, respectively, while the variant transporter seems to
secure these drugs more tightly, with predicted binding energies of
8.1 kcal/mol for ciprofloxacin and7.1 kcal/mol for florfenicol.
These findings suggest that the amino acid changes enhance drug
binding in the cmeB variant.
Rising prevalence of RE-CmeABC in C. jejuni isolates. To
understand the epidemiological significance of RE-CmeABC, we
examined its distribution among 2,002 Campylobacter isolates
(1,458 of C. coli and 544 of C. jejuni) derived from chickens and
swine in China from 2012 to 2014 (Table 2). Among the isolates
examined, 236 (11.8%) carried RE-CmeABC, including 189 C. je-
juni and 47 C. coli isolates (Table 2). The percentage of Campylo-
bacter isolates harboring RE-cmeABC increased from 7.0% (55/
784) in 2012 to 9.8% (60/611) in 2013 and to 19.9% (121/607) in
2014. A chi-square test revealed a significant linear trend in the
ordered years 2012 to 2014 (P 0.0001), indicating an emergent
TABLE 2 Distribution of RE-cmeABC in various Campylobacter isolates
Yr and location of isolation Host (%) no. of positive isolates/total no. of isolates
(%) no. of positive isolates/total no. of isolates
C. jejuni C. coli
2012
Guangdong Chicken (8.9) 11/124 (20.6) 7/34 (4.4) 4/90
Swine (1.0) 2/191 (0.0) 0/1 (1.1) 2/190
Ningxia Chicken (15.2) 5/33 (31.3) 5/16 (0.0) 0/17
Swine (1.4) 3/208 (1.4) 3/208
Shandong Swine (2.8) 2/71 (2.8) 2/71
Shanghai Chicken (20.4) 32/157 (36.2) 25/69 (8.0) 7/88
Total (7.0) 55/784 (30.8) 37/120 (2.7) 18/664
2013
Guangdong Chicken (17.0) 18/106 (66.7) 10/15 (8.8) 8/91
Swine (3.7) 2/54 (100.0) 1/1 (1.9) 1/53
Ningxia Chicken (0.5) 1/196 (0.7) 1/144 (0.0) 0/52
Swine (0.0) 0/24 (0.0) 0/2 (0.0) 0/22
Shandong Chicken (25.0) 18/72 (19.4) 13/67 (100.0) 5/5
Shanghai Chicken (9.8) 13/132 (40.7) 11/27 (1.9) 2/105
Henan Chicken (80.0) 8/10 (100.0) 8/8 (0.0) 0/2
Swine (0.0) 0/17 (0.0) 0/17
Total (9.8) 60/611 (16.7) 44/264 (4.6) 16/347
2014
Guangdong Chicken (15.6) 21/135 (81.3) 13/16 (6.7) 8/119
Ningxia Chicken (6.7) 4/60 (8.1) 3/37 (4.3) 1/23
Swine (30.8) 8/26 (66.7) 4/6 (20.0) 4/20
Shandong Chicken (0.0)0/164 (0.0) 0/1 (0.0) 0/163
Shanghai Chicken (18.2) 14/77 (56.0) 14/25 (0.0) 0/52
Swine (0.0) 0/52 (0.0) 0/52
Henan Chicken (93.7) 74/79 (98.7) 74/75 (0.0) 0/4
Swine (0.0) 0/14 (0.0) 0/14
Total (19.9) 121/607 (67.5) 108/160 (2.9) 13/447
All
Chicken (16.3) 219/1,345 (34.4) 184/534 (4.3) 35/811
Swine (2.6) 17/657 (50.0) 5/10 (1.9) 12/647
Total (11.8) 236/2,002 (34.7) 189/544 (3.2) 47/1,458
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trend of the RE-CmeABC variant in Campylobacter isolates in
China. Remarkably, RE-cmeABC was highly prevalent in the C. je-
juni isolates: 30.8% (37/120) in 2012, 16.7% (44/264) in 2013,
67.5% (108/160) in 2014, and 34.7% (189/544) overall (Table 2).
The chi-square test also revealed a significant linear trend in the
ordered years 2012 to 2014 (P 0.0001). The decreased incidence
in 2013 might be due to the effect of sampling bias, as more than
half (146) of the C. jejuni isolates were from Ningxia Province,
where the prevalence of RE-cmeABC was much lower than that in
the isolates from other regions (Table 2). These results indicated
that RE-cmeABC is increasingly prevalent in C. jejuni isolates in
China. On the contrary, the percentage of C. coli isolates contain-
ing RE-cmeABC was low (ranging from 2.7 to 4.6%) and did not
show a significant linear trend during 2012 to 2014 (P 0.73).
We further analyzed the influence of RE-CmeABC on the dis-
tribution of MICs of ciprofloxacin and florfenicol among the
2,002 Campylobacter isolates (16). Notably, the isolates containing
RE-cmeABC or other types of cmeABC showed a bimodal pattern
of distribution (Fig. 3). This is especially obvious with C. jejuni
and the antibiotic florfenicol. The isolates harboring RE-CmeABC
shifted the MIC distribution to the higher range. A Fisher exact
test confirmed that the MICs of ciprofloxacin and florfenicol were
significantly higher for the isolates containing RE-CmeABC than
for other isolates (P  0.0001). These results indicate that RE-
CmeABC increases antibiotic MICs at the population level.
Molecular typing and phylogenetic analysis of RE-cmeABC-
carrying C. jejuni and C. coli isolates. To determine if RE-
cmeABC-carrying Campylobacter isolates were genetically related,
51 isolates (36 of C. jejuni and 15 of C. coli) representing different
regions, years, host species, and antimicrobial susceptibility pat-
terns were selected for pulsed-field gel electrophoresis (PFGE)
analysis by SmaI digestion (Fig. 4I and II). With 80% genetic sim-
ilarity as the cutoff, the 36 C. jejuni isolates were grouped into 17
clusters (PFGE patterns represented by multiple strains) and 24
unique PFGE patterns (PFGE patterns represented by a single
strain) (Fig. 4I), while the 15 C. coli isolates were grouped into 11
clusters and 15 unique PFGE patterns (Fig. 4II). In general, the
C. jejuni isolates from different regions or different years were
FIG 3 Distribution of ciprofloxacin and florfenicol MICs for Campylobacter isolates with RE-cmeABC or other CmeABC types. (a) Distribution of ciprofloxacin
MICs for C. jejuni. (b) Distribution of ciprofloxacin MICs for C. coli. (c) Distribution of florfenicol MICs for C. jejuni. (d) Distribution of florfenicol MICs for
C. coli. In all panels, “Variant” indicates strains that contain RE-cmeABC while “Wildtype” depicts isolates containing a cmeABC operon that is not RE-cmeABC.
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genetically diverse; however, identical PFGE patterns were ob-
tained with some isolates derived from the same region and the
same year. Some examples included the four isolates from Shang-
hai (Fx1-106, Fx1-111, Fx1-6, and Fx-1-28) and the three isolates
from Henan (HNC111, HNC31, and HNC34) (Fig. 4I). Addition-
ally, we did a more detailed analysis of the RE-cmeABC-positive
C. jejuni isolates collected in 2014 from Henan and found that
most of them had the same PFGE pattern (Fig. 4III). These results
indicated that RE-cmeABC-carrying isolates showed both overall
genetic diversity and regional clonality, suggesting that both
clonal expansion and horizontal transmission were involved in
the dissemination of this cmeABC variant.
DISCUSSION
In this study, we identified an emergent CmeABC variant (RE-
CmeABC) that is more potent in the efflux of antibiotics, confer-
ring enhanced resistance to multiple antimicrobials, especially to
florfenicol and fluoroquinolones (Fig. 1; Table 1). Additionally,
RE-CmeABC in conjunction with the C257T mutation in gyrA
confers exceedingly high-level resistance to ciprofloxacin (MIC,
256 mg/liter). This RE-cmeABC variant is especially prevalent in
C. jejuni and is emergent in chickens and swine in China, suggest-
ing that it facilitates the adaptation of Campylobacter in the food-
producing environment, where antibiotics are frequently used.
Genotyping analysis suggested that both clonal expansion and
horizontal transmission are involved in the spread of this unique
CmeABC variant.
The elevated resistance to multiple antimicrobials seen is due
to both overexpression and sequence variation of RE-cmeABC.
Previous studies indicated that overexpression of cmeABC con-
ferred only a moderate, usually 2-fold, increase in the MICs of
several antimicrobials (19, 31). In this study, however, overex-
pressed RE-cmeABC resulted in 32- and 8-fold increases in the
MICs of florfenicol and ciprofloxacin, respectively (Table 1), in-
dicating a much enhanced function of RE-CmeABC. Similar to
well-characterized AcrB (32), CmeB is responsible for the sub-
strate recognition and interaction in the CmeABC efflux system.
Thus, the sequence variations in CmeB likely had the most impact
on its function. Indeed, structural modeling predicted that cipro-
floxacin and florfenicol are bound within the cavity between sub-
domains PC1 and PC2 in both CmeB and its variant transporter
RE-CmeABC (Fig. 2). However, these two transporters utilize dif-
FIG 4 PFGE analysis of representative RE-cmeABC-positive Campylobacter isolates. SmaI was used for digestion. The regions of isolation (provinces and cities)
include Guangdong (GD), Shandong (SD), Ningxia (NX), Henan (HN), and Shanghai (SH). The host species include chickens (C), swine (S), and ducks (D). (I)
Representative RE-cmeABC-positive C. jejuni (CJ) isolates (n 36). With 80% genetic similarity as a cutoff, the C. jejuni isolates were grouped into 17 clusters
(PFGE patterns represented by multiple strains) and 24 unique PFGE patterns. (II) Representative RE-cmeABC-positive C. coli (CC) isolates (n  15). C. coli
isolates were grouped into 11 clusters and 15 unique PFGE patterns. (III) Representative RE-cmeABC-positive C. jejuni isolates from Henan Province in 2014
(n 25). The isolates were grouped into two clusters and three unique PFGE patterns.
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ferent sets of residues to contact these drugs. On the basis of the
prediction, it was found that the variant transporter tends to use
the mutated residues, including I136, V139, I291, V605, and L607,
to bind these drugs, which secure these drugs more tightly than the
typical CmeB protein. Thus, the enhanced function of CmeB in
RE-CmeABC may be explained, at least in part, by its altered
antibiotic-binding kinetics. This possibility remains to be verified
by structural analysis in future studies.
Results of this study also reveal a clear rising trend in the prev-
alence of RE-CmeABC in C. jejuni (Table 2). The difference in the
prevalence of RE-cmeABC between C. jejuni and C. coli is probably
due to the fact that C. coli is intrinsically more resistant to antimi-
crobials than C. jejuni is (16). Thus, under antimicrobial selection,
C. jejuni may have evolved to acquire RE-cmeABC as a means of
enhanced resistance and adaptation. Previously, Cagliero et al.
reported that a multidrug-resistant C. jejuni strain (154KU) iso-
lated in France harbored a cmeB gene that was quite divergent
from the cmeB genes of other Campylobacter strains. Interestingly,
the CmeB amino acid sequence of C. jejuni 154KU was 99.3%
identical to that of RE-CmeABC identified in this study, indicat-
ing that it is a homolog of RE-CmeABC (33). This finding and the
RE-CmeABC homologs recently deposited in GenBank from dif-
ferent countries suggest that this potent variant has emerged in
other countries beyond China. The emergence and increasing
prevalence of RE-CmeABC in China were likely driven by the
extensive use of antimicrobials in animal production. Florfenicol,
fluoroquinolones, macrolides, and tetracyclines are commonly
used to prevent and control bacterial diseases in food animal pro-
duction in China (16). Because of its enhanced function in mul-
tidrug resistance, harboring RE-CmeABC provides Campylobac-
ter with an enhanced ability to adapt in the animal production
environment.
Interestingly, PFGE analysis of the RE-CmeABC-harboring
isolates indicated that they were genetically diverse, despite certain
clonality among isolates from the same region and the same year.
This finding suggests that RE-cmeABC can spread by horizontal
gene transfer. Indeed, we showed under laboratory conditions
that RE-cmeABC was easily transferred between Campylobacter
isolates by natural transformation. Given that Campylobacter is
naturally transformable, it is expected that RE-cmeABC will con-
tinue to increase in prevalence under selection pressure from an-
timicrobial use.
In conclusion, our findings reveal a “super” CmeABC variant
utilized by Campylobacter for enhanced multidrug resistance. It
desensitizes Campylobacter to multiple classes of antibiotics and
promotes the emergence of fluoroquinolone-resistant mutants
under selection pressure. Additionally, RE-CmeABC, together
with GyrA mutations, confers exceedingly high-level resistance to
fluoroquinolone, a key antibiotic used for the treatment of Cam-
pylobacter infections. Thus, dissemination of RE-CmeABC will
likely have a significant impact on the clinical treatment of cam-
pylobacteriosis. Given that RE-cmeABC can be transferred by nat-
ural transformation, it is possible that this variant will continue to
spread in clinical isolates. Thus, enhanced efforts are needed to
prevent its further dissemination. Furthermore, our study reveals
an effective strategy utilized by bacteria for adaptation to antibi-
otic selection. Gaining a specific resistance determinant only al-
lows bacteria to resist a particular antimicrobial, while acquisition
of a functionally enhanced efflux pump empowers bacteria with
simultaneous resistance to multiple classes of antibiotics. Such a
mechanism provides an efficient means for bacterial adaptation to
selection pressure from the use of diverse antimicrobials.
MATERIALS AND METHODS
Campylobacter strains and antimicrobial susceptibility testing. C. coli
DH161 was isolated from a duck slaughterhouse in Shandong Province,
China, in 2009. Additionally, a total of 2,002Campylobacter isolates (1,458
of C. coli and 544 of C. jejuni) were tested for the presence of RE-cmeABC
(Table 2). These Campylobacter strains were isolated from cecal contents,
carcasses, and feces of swine and chickens from Shandong, Henan,
Ningxia, Guangdong, and Shanghai under the surveillance program for
antimicrobial resistance in Campylobacter of animal origin during 2012 to
2014 (16, 18). All of the Campylobacter strains were grown on Mueller-
Hinton (MH) agar (Sigma-Aldrich, St. Louis, MO) at 42°C under mi-
croaerobic conditions (5% O2, 10% CO2, 85% N2).
Antimicrobial susceptibility testing was conducted by the standard
agar dilution method according to the guidelines of the Clinical and Lab-
oratory Standards Institute (34). C. jejuni ATCC 33560 was used for qual-
ity control. All of the experiments described above were repeated three
times.
Detection of florfenicol and fluoroquinolone resistance determi-
nants. Mutations involved in florfenicol resistance in the 23S rRNA gene
and L4 and L22 ribosomal protein genes in the strains used in this study
were detected by PCR and DNA sequencing. In addition, the floR, fexA,
fexB, cfr, and optrA genes, known to confer resistance to florfenicol, were
examined by PCR. The primers used are listed in Table S3 in the supple-
mental material. A mismatch amplification mutation assay (MAMA)-
PCR was performed to detect the C257T (Thr-86-Ile) mutation in the
quinolone resistance-determining region of the gyrA gene (35). More-
over, the strains were screened for the presence of parC and PMQR genes
by PCR amplification with the primers in Table S3.
Natural transformation. Natural transformation was conducted as
described previously (36). Briefly, genomic DNA of C. coli DH161 served
as the donor DNA and C. jejuni NCTC 11168, susceptible to florfenicol,
was used as the recipient strain. The transformants (including NT161)
were selected on MH agar plates containing florfenicol (4 mg/liter).
Transformation without donor DNA was used as a negative control.
Transformants were examined for known mutations involved in florfeni-
col resistance.
The cmeABC operon in NCTC 11168 was replaced with RE-cmeABC
of DH161 by natural transformation. The donor DNA was the PCR prod-
uct of the entire RE-cmeABC operon. Briefly, RE-cmeABC was amplified
from DH161 with primers CmeABC-F and CmeABC-R (see Table S3 in
the supplemental material) and cloned into the pMD19-T vector (Ta-
KaRa). This suicide vector was then transferred intoC. jejuniNCTC 11168
by natural transformation (36), and the transformants (11168-V1 and
11168-V2) were selected on MH agar plates containing florfenicol (2 to
4 mg/liter). 11168-V1 and 11168-V2 have the same RE-cmeABC coding
sequence, while 11168-V1 has the same promoter as DH161 and
11168-V2 has the same promoter as NCTC 11168. PCR and DNA se-
quencing were performed to confirm the presence of RE-cmeABC in these
transformants. The three copies of 23S rRNA, as well as the L4 and L22
ribosomal protein genes, were also examined for potential mutations by
PCR and DNA sequencing.
Random transposon mutagenesis. To identify the determinant in-
volved in florfenicol resistance, we conducted random mutagenesis of
transformant NT161 with the EZ-Tn5KAN-2 Insertion kit (Epicen-
tre Biotechnologies) (18). The transposon mutants were screened on MH
agar plates containing kanamycin (50 mg/liter). Clones selected on the
kanamycin plates were inoculated simultaneously onto two types of MH
agar plates containing kanamycin (50 mg/liter) and florfenicol (4 mg/
liter), respectively. Clones that failed to grow on plates containing 4 mg/
liter florfenicol but grew on plates containing kanamycin at 50 mg/liter
were selected to confirm the kanamycin resistance gene aphA-3 insertion
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by PCR and its flanking regions by a modified random primer walking
sequencing method (37).
Whole-genome sequencing. The whole genome of transformant
NT161 was sequenced on an Illumina HiSeq 2000 platform at the Hudson
Alpha Institute (Huntsville, AL). The backbone genome sequence of
NT161 is NCTC 11168.
Introduction of RE-cmeABC into C. jejuni 81-176. The native cme-
ABC operon in C. jejuni 81-176 was deleted and replaced with a chloram-
phenicol resistance gene (cat) by the homologous-recombination method
(19). The intact RE-cmeABC operon from DH161 was amplified with
primers cmeAKpnI-F and cmeCKpnI-R. The amplicon was digested with
KpnI and ligated into the corresponding sites of plasmid pUC-cadF-
ermB-cj1476c (38). pUC-cadF-ermB-cj1476c contains a macrolide resis-
tance gene (ermB) between the sequences homologous to the cadF and
cj1476c genes. The constructed suicide plasmid pUC-cadF-RE-cmeABC-
ermB-cj1476c was used to introduce RE-cmeABC into the 81-176 cmeABC
deletion mutant strain. The transformants (81-176-V) were selected on
MH agar plates containing erythromycin (10 mg/liter) and verified by
PCR and DNA sequence analysis.
Selection of the C257T mutation in the gyrA gene. In order to assess
the level of resistance to fluoroquinolones in strains coharboring RE-
cmeABC and the DNA gyrase C257T mutation, the C257T mutation in
gyrA was selected in C. jejuni NT161 and NCTC 11168 by exposure to
ciprofloxacin. Briefly, strains NCTC 11168 and NT161 were grown over-
night on antibiotic-free MH agar and then resuspended in MH broth to
achieve a density of 109 CFU/ml. Each suspension of 100l was separately
spread onto MH agar plates supplemented with ciprofloxacin (4 mg/liter)
and cultivated at 42°C for 2 to 3 days under microaerophilic conditions.
Colonies on the plates were selected, and the C257T mutation in gyrA was
confirmed by MAMA-PCR (35).
Determining frequencies of emergence of fluoroquinolone-
resistant mutants. The frequency of emergence of fluoroquinolone-
resistant Campylobacter mutants was detected as described previously
(25). Briefly, strains NCTC 11168 and NT161 were grown on MH agar
plates for 24 h at 42°C under microaerobic conditions (5% O2, 10% CO2,
85% N2). The cells were collected and suspended in 500 l of MH broth.
The total CFU count was determined by serial dilution and plating. The
same amount (100 l) of a bacterial suspension of each strain was plated
onto MH agar plates containing four different concentrations of cipro-
floxacin, i.e., 1.25, 4, 8, and 16 mg/liter, respectively. The frequency of
emergence of fluoroquinolone-resistant mutants was calculated as the
ratio of the CFU counts on ciprofloxacin-containing MH agar plates to
the CFU counts on ciprofloxacin-free MH agar plates after 48 h of incu-
bation at 42°C under microaerobic conditions. This experiment was re-
peated three times.
Sequence analysis and structure prediction of CmeB. The Protein
Basic Local Alignment Search Tool (BLASTP) was used to search Campy-
lobacter CmeB protein sequences (taxid:194 and taxid:72294) in the data-
base of nonredundant protein sequences. The maximum number of tar-
get sequences was set at 250. Three sequences were eliminated from the
analysis because of the low query coverage. A total of 247 sequences from
C. jejuni (n 105), C. coli (n 98), and other species (n 44) were used
for further analysis. ClustalW was used to carry out multiple-sequence
alignments of the 247 searched sequences together with CmeB of DH161
and a multidrug efflux RND transporter (accession no. WP_044694729.1)
from E. coli (used as the outgroup). The maximum-likelihood phyloge-
netic tree was constructed with MEGA6.
The structures of CmeB in NCTC 11168 and DH161 were predicted by
homology modeling with the Modeller program (27). The predictions
were based on profile-profile sequence alignments (FFAS03) (39) by uti-
lizing the structure of MexB (2V50) (26) as the template. The predicted
structures were idealized with PHENIX (40) and then input into AutoD-
ock Vina (version 1.1.2) (30). The structures of both ligands, ciprofloxa-
cin and florfenicol, were obtained from the PubChem database (http://
pubchem.ncbi.nlm.nih.gov). AutoDockTools (41) was then used to
prepare the ligand files. The protein was set as a rigid structure, whereas
the conformation of each ligand was optimized during all modeling and
docking procedures. The iterated local search global optimizer algorithm
was employed to predict the binding free energies for these compounds.
Real-timeRT-PCRanalysis of cmeABC transcription.Real-time RT-
PCR was conducted to determine the expression levels of cmeABC in
various strains as described previously (31). Briefly, NCTC 11168, 11168-
V1, and 11168-V2 were grown in MH broth for 16 h at 42°C under mi-
croaerobic conditions. Two volumes of Sample Protector for RNA/DNA
(TaKaRa) were added to the cultures to stabilize the total bacterial RNA.
The mixtures were incubated at room temperature for 5 min, and then
bacterial cells were collected by centrifugation at 5,000  g for 10 min.
Total RNA was purified by using an RNeasy minikit (Qiagen) according to
the instructions included. Purified RNA was treated with TURBO DNA-
free (Ambion) to remove DNA contamination. The primers used for real-
time PCR are shown in Table S4 in the supplemental material. The two
pairs of primers were designed to target the conserved regions of cmeA and
cmeC, respectively, in NCTC 11168, 11168-V1, and 11168-V2. Ten-fold
dilution series between 2.5 pg and 25 ng were made for RNA templates of
NCTC 11168, 11168-V1, and 11168-V2 to generate the standard curve.
RT-PCR assays were performed with the One Step SYBR PrimeScript
PLUS RT-PCR kit (Perfect Real Time) (TaKaRa). The thermal cycling
conditions were as follows: 10 min at 50°C, 5 min at 60°C, 5 min at 95°C,
and then 40 cycles of 10 s at 95°C and 30 s at 58°C. Samples were normal-
ized by using 16S RNA as an internal standard. Three biological replicates
were prepared for each strain, and three technical replicates were per-
formed for each RNA template. The relative changes (n-fold) in cmeABC
transcription between cmeABC variant strains (11168-V1 and 11168-V2)
and NCTC 11168 were calculated by the 2CT method as described
previously (42).
Ciprofloxacin accumulation assay. The ciprofloxacin accumulation
assay used was based on the method described previously (18). Overnight
broth culture of C. jejuni was harvested and washed once in phosphate-
buffered saline (PBS; pH 7.2), and the cell density was adjusted to an
optical density at 600 nm of 20. Three different tubes were prepared for
each sample. A cell suspension of each strain was incubated for 10 min at
37°C in a normal atmosphere, and then ciprofloxacin was added to a final
concentration of 10 mg/liter. Aliquots (0.5 ml) were taken after 3, 5, 10,
and 20 min and immediately diluted with 2.5 ml of ice-cold PBS. Bacterial
cells were harvested by centrifugation at 4°C at 6,000  g for 5 min and
washed once with 2 ml of ice-cold PBS. Bacterial cells were resuspended in
0.2 ml of 0.1 M glycine hydrochloride (pH 3.0) and shaken at room tem-
perature for 16 h. The supernatant was taken after centrifugation at 15,000
 g for 5 min, and fluorescence was measured with FLUOstar Omega with
excitation and emission wavelengths of 279 and 447 nm, respectively. A
standard curve was prepared by measuring the fluorescence emitted from
0.1 M glycine hydrochloride containing serially diluted ciprofloxacin and
used to determine the concentration of ciprofloxacin in the samples.
Detection of RE-cmeABC inCampylobacter isolates. To measure the
distribution of RE-cmeABC in Campylobacter isolates, primers BV-F (5=-
CGTATTGCACGATTATTTGGAC) and BV-R (5=-ATCGTTATCAAAC
CCTCTATGTGCC) were designed according to the sequences specific for
the cmeB variant in DH161 and used to specifically amplify the cmeABC
variant. The PCR cycling conditions were as follows: initial denaturation
at 95°C for 5 min; 30 cycles of 95°C for 30 s, 59°C for 30 s, and 72°C for 40 s;
and a final extension at 72°C for 7 min. NCTC 11168 was used as a nega-
tive control, while DH161 was used as a positive control in the PCRs.
Representative PCR products were selected for DNA sequencing analysis
for verification.
PFGE. Representative Campylobacter isolates containing RE-cmeABC
were genotyped by PFGE, which was conducted with a CHEF-DR III
apparatus (Bio-Rad Laboratories, Hercules, CA) in accordance with the
protocol for Campylobacter (43). The DNA of Campylobacter was digested
with SmaI, and the DNA of SalmonellaH9812 digested with XbaI was used
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as the reference marker. The results were analyzed with the InfoQuest FP
software version 4.5 (Bio-Rad Laboratories).
Accession number. The cmeABC variant sequences of the strains in-
volved in this study have been submitted to GenBank under accession
number KT778507.
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